Tech Company Financing Transactions

BioEclipse Therapeutics Funding Round

Revelis Capital, DEFTA Partners and Foothill Ventures participated in a $7.7 million Series A funding round for BioEclipse Therapeutics. The round was announced on 6/25/2019.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
BioEclipse plans to use proceeds from the Series A-1 financing to initiate human trials of CRX-100, BioEclipse's patented, first-in-class, intravenous, tumor targeted combination immunotherapy.

Company Information

Company Status
Private & Independent
Mailing Address
329 Oyster Point Blvd. 3rd Floor S.
San Francisco, CA 94080
Email Address
BioEclipse Therapeutics is an emerging, clinical-stage biopharmaceutical company committed to delivering first-in-class, curative immune-oncology therapeutics to patients with cancer. Our focus is on currently untreatable cancers where our unique approach may be able to address needs of patients with cancers that most think not possible.
BioEclipse Therapeutics LinkedIn Company Profile
Social Media
BioEclipse Therapeutics Company Twitter Account
Company News
BioEclipse Therapeutics News
BioEclipse Therapeutics on Facebook
BioEclipse Therapeutics on YouTube

Management Team

Email & Social
Catherine Sohn
  Catherine Sohn LinkedIn Profile  Catherine Sohn Twitter Account  Catherine Sohn News  Catherine Sohn on Facebook
Chief Executive Officer
Pamela Contag
  Pamela Contag LinkedIn Profile  Pamela Contag Twitter Account  Pamela Contag News  Pamela Contag on Facebook
Chief Financial Officer
Benjamin Carter
  Benjamin Carter LinkedIn Profile  Benjamin Carter Twitter Account  Benjamin Carter News  Benjamin Carter on Facebook
Christopher Contag
  Christopher Contag LinkedIn Profile  Christopher Contag Twitter Account  Christopher Contag News  Christopher Contag on Facebook
Robert Negrin
  Robert Negrin LinkedIn Profile  Robert Negrin Twitter Account  Robert Negrin News  Robert Negrin on Facebook



Browse more venture capital transactions:

Prev: 6/25/2019: Alma venture capital transaction
Next: 6/25/2019: Corinth MedTech venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary